Figure 2
Figure 2. IL-4 reverses impaired efferocytosis of X-CGD MØs. RPMØs were plated for 24 hours and treated with 100 ng/mL each of LPS and IFNγ or 10 ng/mL IL-4 and/or IL-10 for 20 hours (A,B), or 10 ng/mL IL-4 for the times indicated (C), or with indicated doses of IL-4 for 20 hours (D). Efferocytosis assays were performed as described in “Efferocytosis assay.” Data represent means plus or minus SEM; N = 5 experiments. *P value less than or equal to .005 compared with WT control; #, P value less than or equal to .005 compared with X-CGD control. Significant differences demonstrated for RPMØs in Figure 1 were maintained but not designated for clarity.

IL-4 reverses impaired efferocytosis of X-CGD MØs. RPMØs were plated for 24 hours and treated with 100 ng/mL each of LPS and IFNγ or 10 ng/mL IL-4 and/or IL-10 for 20 hours (A,B), or 10 ng/mL IL-4 for the times indicated (C), or with indicated doses of IL-4 for 20 hours (D). Efferocytosis assays were performed as described in “Efferocytosis assay.” Data represent means plus or minus SEM; N = 5 experiments. *P value less than or equal to .005 compared with WT control; #, P value less than or equal to .005 compared with X-CGD control. Significant differences demonstrated for RPMØs in Figure 1 were maintained but not designated for clarity.

Close Modal

or Create an Account

Close Modal
Close Modal